Published in Drug Week, March 10th, 2006
The company announced patient recruitment has surpassed the half-way point in the CoFactor multi-national phase IIb clinical trial for metastatic colorectal cancer which was initiated in May 2005. The company also announced an update regarding its planned phase III clinical studies for CoFactor.
The first phase III study will evaluate CoFactor in the first-line treatment of metastatic colorectal cancer. The second proposed phase III study would evaluate CoFactor in a third-line setting for advanced breast cancer. CoFactor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week